Adjuvant Therapy
37
13
17
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
2.7%
1 terminated out of 37 trials
75.0%
-11.5% vs benchmark
16%
6 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (37)
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:
Estimation and Prediction of Individual Benefit From Postoperative Adjuvant Transcatheter Arterial Chemoembolization For Patients With Hepatocellular Carcinoma
An Antibody-armored Dendritic Cell in Patients With Solid Tumors
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer
Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study
Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer
Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer
MRD in PAAD Adjuvant Therapy
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma